Google's advertising policy identifies speculative and experimental medical treatments, including cell therapies and gene therapies, as a restricted category in the United States. Ads promoting these treatments for clinical use are not eligible to run, and Google can disapprove ads or suspend accounts for violations found anywhere in the advertised experience.
Because the policy looks at the full advertised experience, a compliant-looking ad can still violate the policy if it sends traffic to a landing page that makes disease or outcome claims about an unapproved cell or exosome product. The same content standard that applies to organic marketing under FTC guidance tends to apply here as well: specific, substantiated claims about composition and process are lower risk than general claims about what a product does for a condition.
B2B or educational framing does not establish ad eligibility. Review the Google Ads policy before planning a campaign. Clinics considering their own advertising for services involving these products should review the same policy rather than assume educational or procurement-focused content is automatically compliant.
Clinics or distributors running paid advertising should know that disease or outcome claims, not just the word 'stem cell,' are what trigger this restriction, so ad and landing page content need to match.